NCT04987736

Brief Summary

An outbreak of the novel coronavirus nCoV-19 (SARS-CoV-2), responsible for the coronavirus disease-19 (COVID-19), was first detected in Hubei province, Wuhan, China, on December 31, 2019. It has rapidly spread globally with approximately 157,343,044 confirmed cases and 3,278,510 deaths till 7th May, 2021 \[1\]. World Health Organization (WHO) declared COVID- 19 pandemic on 11th March 2020. The world is facing the second wave of Coronavirus Disease 2019 (COVID-19) pandemic which is the most troublesome challenge to public health. The second wave is running and nobody knows where we are in the course of this disease. It becomes a significant challenge for the public health, science, and medical sectors \[2\]. According to the World Health Organization, about 80% of infections are mild or asymptomatic, 15% result in moderate to severe symptoms (requiring oxygen) and about 5% are critical infections, which require ventilation. We are learning something new every day. Our understanding of the pandemic is growing and changing daily. The world is focusing on the short term - flattening the curve, treating the sick and discovering a vaccine. But there is more to this pandemic than the short term. We know a lot about the transmission and clinical feature of COVID-19, but relatively little about what happens after someone recovers. Much is still unknown about how COVID-19 will affect people over time. There's still much to be learned from those who have recovered from COVID-19.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
302

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jul 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2021

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

August 1, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

August 3, 2021

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2021

Completed
Last Updated

August 3, 2021

Status Verified

August 1, 2021

Enrollment Period

4 months

First QC Date

August 1, 2021

Last Update Submit

August 1, 2021

Conditions

To Assess Long-term Effects of COVID-19 in Patients Who Were Affected With COVID -19

Keywords

long-term effectsCOVID-19RT-PCR +vE

Outcome Measures

Primary Outcomes (1)

  • Assessment of long-term effects (complications) of COVID-19 in the southern part of Bangladesh

    At the end of study, we will be able to assess long-term effects of COVID-19 in patients of southern part of Bangladesh and to know its incidence.

    6 Months

Study Arms (1)

COVID-19 (RT-PCR +ve) patients

Diagnostic Test: RT-PCR

Interventions

RT-PCRDIAGNOSTIC_TEST

COVID 19 diagonostic test

COVID-19 (RT-PCR +ve) patients

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

COVID -19 (RT-PCR +ve) patients from 1st July to 30th December, 2020 recorded in PCR Lab of Sher-E-Bangla Medical College Hospital, Barishal.

You may qualify if:

  • COVID-19 (RT-PCR +ve) patients age 20 years and above
  • Those patients whose mobile numbers are recorded in the register
  • Those patients who/their attendants are available on mobile phone

You may not qualify if:

  • Persons below 20 years of age
  • Those patients whose mobile numbers are not recorded in the register
  • Those patients who/their attendants are not available on mobile phone
  • Those who died by this time from causes unrelated to COVID-19

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

HN Sarker

Barishal, 1207, Bangladesh

RECRUITING

Related Publications (3)

  • WHO, Coronavirus disease 2019 (COVID-19) situation report, 7 May 2021, WHO Bull, 2021

    RESULT

  • de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34. doi: 10.1038/nrmicro.2016.81. Epub 2016 Jun 27.

    PMID: 27344959RESULT

  • Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y, Zheng C. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020 Apr;20(4):425-434. doi: 10.1016/S1473-3099(20)30086-4. Epub 2020 Feb 24.

    PMID: 32105637RESULT

Related Links

MeSH Terms

Conditions

COVID-19

Interventions

COVID-19 Nucleic Acid Testing

Condition Hierarchy (Ancestors)

Pneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Intervention Hierarchy (Ancestors)

COVID-19 TestingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisInvestigative Techniques

Central Study Contacts

HN Sarker, MBBS

CONTACT

+8801715079037hnsarker@gmail.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 1, 2021

First Posted

August 3, 2021

Study Start

July 1, 2021

Primary Completion

October 30, 2021

Study Completion

December 30, 2021

Last Updated

August 3, 2021

Record last verified: 2021-08

Locations

BA(1)